At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02252 MEDBOT-B
Trading 03-02 09:54:13
26.040
-1.900
-6.80%
High27.300Low26.000Vol1.85M
Open27.000D1 Closing27.940Amplitude4.65%
Mkt Cap26.86BTradable Cap26.68BTotal Shares1.03B
T/O49.02MT/O Rate0.18%Tradable Shares1.02B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Hangzhou Sciwind Biosciences and Pfizer China Announce Strategic Cooperation Agreement on Commercialisation of New Generation of Ecnoglutide Injection
THOMSON REUTERS  ·  02-24
Hangzhou Sciwind Biosciences and Pfizer China Announce Strategic Cooperation Agreement on Commercialisation of New Generation of Ecnoglutide Injection
Hong Kong shares slip after Lunar New Year break
Reuters  ·  02-20
Hong Kong shares slip after Lunar New Year break
HK Robotics Stocks Jump. Dobot Up 18%; Shoucheng And Robosense Up 10%; Ubtech, Yunji And Sanhua Up 6%; Geekplus Up 4%
Tiger Newspress  ·  02-20
HK Robotics Stocks Jump. Dobot Up 18%; Shoucheng And Robosense Up 10%; Ubtech, Yunji And Sanhua Up 6%; Geekplus Up 4%
JPMorgan Maintains Overweight Rating on MEDBOT-B (02252) as Global Expansion Accelerates
Stock News  ·  02-16
JPMorgan Maintains Overweight Rating on MEDBOT-B (02252) as Global Expansion Accelerates
MEDBOT-B Receives HKEX Approval for Full Circulation of H Shares
Deep News  ·  02-16
MEDBOT-B Receives HKEX Approval for Full Circulation of H Shares
Shanghai MicroPort MedBot (SEHK:2252) Valuation After Global Toumai Robot Orders And Remote Surgery Progress
Simply Wall St.  ·  02-14
Shanghai MicroPort MedBot (SEHK:2252) Valuation After Global Toumai Robot Orders And Remote Surgery Progress
MicroPort MedBot (2252) Receives Approval for H Share Full Circulation
Bulletin Express  ·  02-13
MicroPort MedBot (2252) Receives Approval for H Share Full Circulation
MEDBOT-B Granted Listing Approval for Full H-Share Circulation
Stock News  ·  02-13
MEDBOT-B Granted Listing Approval for Full H-Share Circulation
MEDBOT-B's Toumai® Surgical Robot Surpasses 200 Global Commercial Orders
Stock News  ·  02-12
MEDBOT-B's Toumai® Surgical Robot Surpasses 200 Global Commercial Orders
Shanghai MicroPort MedBot Receives Over 200 Orders for Toumai Surgical Robot
Reuters  ·  02-12
Shanghai MicroPort MedBot Receives Over 200 Orders for Toumai Surgical Robot
AI Technology Expected to Enable Autonomous Operation of Surgical Robots, Institutions Foresee Valuation Upside for Industry Chain Companies
Stock News  ·  02-12
AI Technology Expected to Enable Autonomous Operation of Surgical Robots, Institutions Foresee Valuation Upside for Industry Chain Companies
MicroPort MedBot (02252) Announces January 2026 Monthly Return with Unchanged Share Capital
Bulletin Express  ·  02-05
MicroPort MedBot (02252) Announces January 2026 Monthly Return with Unchanged Share Capital
Shanghai MicroPort's Application to List Unlisted Stocks on HKeX Approved by Chinese Regulators
MT Newswires Live  ·  02-05
Shanghai MicroPort's Application to List Unlisted Stocks on HKeX Approved by Chinese Regulators
MEDBOT-B Receives CSRC Filing Notice for H-Share Full Circulation Application
Stock News  ·  02-04
MEDBOT-B Receives CSRC Filing Notice for H-Share Full Circulation Application
JPMorgan Slightly Trims MEDBOT-B (02252) Target Price to HK$41, Remains Top Pick in China MedTech
Stock News  ·  01-27
JPMorgan Slightly Trims MEDBOT-B (02252) Target Price to HK$41, Remains Top Pick in China MedTech
Citi: MEDBOT-B (02252) Last Year's Revenue Growth Exceeded Expectations; Fee Standardization Policy Marks Industry Milestone
Stock News  ·  01-22
Citi: MEDBOT-B (02252) Last Year's Revenue Growth Exceeded Expectations; Fee Standardization Policy Marks Industry Milestone
JPMorgan: Mainland Surgical Robot Service Pricing Standardization Boosts MEDBOT-B (02252) Commercial Prospects
Stock News  ·  01-22
JPMorgan: Mainland Surgical Robot Service Pricing Standardization Boosts MEDBOT-B (02252) Commercial Prospects
MEDBOT-B (02252) Surges Over 4%, Forecasts Over 50% Reduction in Adjusted Net Loss for Last Year
Stock News  ·  01-22
MEDBOT-B (02252) Surges Over 4%, Forecasts Over 50% Reduction in Adjusted Net Loss for Last Year
Hong Kong Stock Concept Tracking | Surgical Robot Price Approval Lands, Institutions Focus on Commercial Advancement of Domestic Surgical Robots (Including Concept Stocks)
Stock News  ·  01-22
Hong Kong Stock Concept Tracking | Surgical Robot Price Approval Lands, Institutions Focus on Commercial Advancement of Domestic Surgical Robots (Including Concept Stocks)
BRIEF-Shanghai Microport Medbot Sees Adjusted Net Loss Of Not More Than RMB240 Million For Year
Reuters  ·  01-21
BRIEF-Shanghai Microport Medbot Sees Adjusted Net Loss Of Not More Than RMB240 Million For Year

Introduction

Company Name.
MEDBOT-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Shanghai MicroPort MedBot Group Co Ltd is a China-based company primarily engaged in the provision of intelligent surgery total solutions. The Company’s main business is engaged in the research and development, manufacturing and sale of surgical robots. The Company’s products include Toumai Laparoscopic Surgical Robot, Skywalker Orthopedic Surgical Robot, R-one vascular intervention surgical robot, Microport Medbot and other products, covering surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice and percutaneous surgical procedures. The Company conducts its business in the domestic and overseas markets.
Issue price:
--